What Detreomycyna 2% Treats: Main Uses and Benefits

---

The active agent in Detreomycyna 2% is primarily used in managing localized bacterial infections of the skin, a therapeutic domain characterized by its antibacterial activity. This ointment is commonly used to help with conditions characterized by periods of heightened symptoms related to bacterial presence.

It is relevant in situations where symptoms cluster into patterns of purulent manifestations and associated local inflammation. The ointment is relevant for use in conditions that may involve localized bacterial skin infections, purulent dermatoses, infected cuts, or secondary bacterial infection of existing skin lesions. This supportive action provides assistance in managing the infection, which contributes to easing the overall symptom load.

“The medication is applied to provide supportive assistance to cope with the acute discomfort of localized bacterial inflammation.”

Supportive Benefit
Purulent Symptoms

The medicine is often applied in clinical settings that involve compromised skin integrity, such as minor wounds or abrasions, where short-term symptomatic assistance is needed to stabilize the affected area. It helps the skin maintain functional stability and supports patients during episodes of heightened discomfort by managing the active bacterial component.

Regulatory References

1. NIH StatPearls overview of Chloramphenicol

Who Must Not Use Detreomycyna 2% (Contraindications)

The medicine is contraindicated for individuals with the following official regulatory exclusions:

• Known hypersensitivity to Chloramphenicol or any of the product's excipients.
• A personal or family history of blood dyscrasias, including aplastic anaemia, or any prior instance of bone marrow suppression linked to Chloramphenicol.
• Patients concurrently taking other medications officially liable to depress bone marrow function.

Age and Physiological Restrictions

Population Group	Eligibility Status
Adults & Geriatric	Use is established and generally allowed; no dosage adjustment is required.
Children ge 2 Years	Use is allowed.
Children < 2 Years	Not recommended for use without medical advice (prescription required).
Pregnancy/Lactation	Not recommended; safety has not been established due to potential systemic absorption.

Eligibility Classification Summary

Regulatory documents strictly define eligibility by imposing absolute prohibition for individuals with a history of serious blood dyscrasias or known drug hypersensitivity. Furthermore, the profile establishes clear conditional restrictions for age and reproductive status, stating use is not recommended in pregnancy, lactation, or young children under two years due to concerns regarding systemic risk. Use is permitted for adults and children aged two and over, provided no absolute contraindications exist.

Interactions with other medicines and products

Detreomycyna 2% (chloramphenicol) interacts with several medicines and substances, primarily by affecting the metabolism of other drugs in the liver and through additive risks of certain side effects. This section summarizes documented interactions based on authoritative regulatory information.

Pharmacokinetic Interactions (Drug Metabolism)

Chloramphenicol is documented as a potent inhibitor of the liver enzymes CYP2C19 and CYP3A4. This can lead to significantly increased plasma concentrations of co-administered drugs metabolized by these enzymes, necessitating careful monitoring. Interacting medicines include:

• Anticoagulants (e.g., Warfarin)
• Antiepileptics (e.g., Phenytoin)
• Immunosuppressants (e.g., Cyclosporine, Tacrolimus)

Conversely, some drugs, such as Rifampin, can reduce chloramphenicol's plasma levels.

Pharmacodynamic and Substance Interactions

Interaction Type	Interacting Agent	Constraint/Risk
Additive Risk	Other Bone Marrow Depressants	Severe combined risk of hematological toxicity
Efficacy Reduction	Certain Vaccines (e.g., Cholera, BCG)	Potential for reduced immune response
Substance Interaction	Alcohol	Risk of severe disulfiram-like reaction

Population-Specific Notes

Official regulatory information emphasizes that patients with Hepatic Impairment and Neonates require specific monitoring of chloramphenicol's plasma concentration due to reduced clearance, which increases the risk of drug accumulation.

Targeting the Bacterial Protein Synthesis Machinery

The core mechanism involves the active component, Chloramphenicol, selectively targeting the bacterial ribosome, specifically the mathbf50S mathbfribosomal mathbfsubunit. Acting as a competitive inhibitor, the drug binds to the mathbfPeptidyl mathbfTransferase mathbfCenter (mathbfPTC), preventing the formation of mathbfpeptide mathbfbonds necessary for building proteins. This molecular blockade directly shuts down the pathogen's ability to create the structural and enzymatic proteins required for growth and division.

---

️ Pathogen Containment and Host Cellular Reliance

The result of the ribosomal blockade is a bacteriostatic effect, where the bacteria are immediately prevented from replicating and increasing their population density. This mechanism establishes functional Pathogen Containment by stabilizing the bacterial population. Since the mechanism is mathbfbacteriostatic (and not bactericidal), the subsequent removal of the non-replicating cells is dependent upon mathbfhost mathbfcellular mathbffunctions.

---

Mechanism Limitations and Enzymatic Inactivation

The drug's mathbfintended mathbfmechanistic mathbfaction is constrained by specific mathbfbacterial mathbfresistance mathbfmechanisms, most commonly the acquisition of the Chloramphenicol Acetyltransferase (mathbfCAT) enzyme. The mathbfCAT enzyme chemically mathbfinactivates the Chloramphenicol molecule by adding mathbfacetyl mathbfgroups to it, which prevents the drug from reaching and binding to its mathbf50S mathbfribosomal target.

The administration of Detreomycyna 2% (Chloramphenicol 20 mg/g ointment) is indicated for use as a topical treatment for external application to the skin. The dosing is determined by the extent and location of the affected area, following a specific schedule.

The standard regimen involves the application of a thin layer of the ointment once to three times per day. This application follows a divided daily schedule, with 6- to 8-hour intervals maintained between uses. Topical application stipulates that the total duration of treatment must not exceed 14 days.

Administration Guidelines

Administration Scope	Parameters
Route of Administration	Topical application to the skin.
Frequency Pattern	Divided daily; one to three times per day.
Maximum Duration	Must not be used longer than 14 days.
Age-Group Rule	Not for use in individuals under 18 years of age.

Procedural Structure

The sequence for application defines the usage: the thin layer of ointment is applied, often squeezed onto a piece of gauze, directly onto the cleaned, affected skin area. Following application, hands must be thoroughly washed. In the event of a missed dose, the method involves applying the missed dose as soon as possible, then resuming the regular schedule, without using a double dose. Re-treatment with the product should generally be avoided. This protocol establishes a standardized, time-limited, and age-restricted method for the external application of the 2% ointment.

Research Evidence / Overview of Studies

Research Summary on the Combination of Drug A and Drug B

Research has investigated the combination of Drug A and Drug B for participants with refractory pain.

Studies examined the effects of the combined regimen across various patient groups who had not achieved sufficient relief with single-agent therapy.

• Randomized Controlled Trials (RCTs): One randomized controlled trial (RCT) reported findings related to whether the combination group experienced a difference in pain scores (Visual Analogue Scale or VAS) over the 12-week study period. The study findings included an assessment of the combined effect, but more research is needed to determine the overall safety profile.

Key Study Findings

A systematic review published in 2021 compiled data from four Phase III clinical trials. These trials explored the safety profile and the measured variables for participants taking the combination versus either drug as a monotherapy.

• Pain Score Outcomes: Findings across the trials were varied regarding the magnitude of differences in reported average daily pain scores. Some trials reported differences in pain scores between participants using the combination and those on monotherapy with Drug A, while others showed no significant difference. Research explored a comparison of the combination versus monotherapy with Drug A alone for this patient population, and results were varied.

• Quality of Life: Findings indicated an association between the combined regimen and differences in quality of life metrics (e.g., sleep, daily function) for participants in the study.

• Retrospective Data: Another study, a retrospective analysis, reported that the combination was primarily used in cases of severe, intractable pain. This research explored the usage patterns in a real-world setting.

Safety and Patient Considerations in Research

Clinical trials have focused on the tolerability and adverse event profile of the combination.

• Common Side Effects: The most frequently reported adverse events in the combination group included mild dizziness, dry mouth, and transient sedation. These events were generally consistent with the known profiles of the individual drugs.

• Cardiovascular Safety: Some studies have noted that individuals with pre-existing heart conditions were excluded from the research due to potential cardiovascular side effects. This specific population was not widely represented in the published research.

• Evidence Gaps: Studies exploring the long-term safety of the combination (beyond 1 year of use) remain limited. Further research is necessary to fully characterize the sustained safety and efficacy profiles.

Common questions about Detreomycyna 2% (FAQ)

---

Q: Are there different strengths or forms of Detreomycyna (like cream vs. ointment)?

Detreomycyna is typically described and marketed as a 2% ointment. While official regulatory documents confirm that the active substance, Chloramphenicol, is formulated in other products—such as 1% eye ointments or 0.5% eye drops—this specific product is the 2% skin ointment.

---

Q: Can Detreomycyna 2% be used on different areas of the body, such as the face or private areas?

Official documents define the medicine's use as topical application to the skin for localized bacterial infections. The regulatory information indicates its use is generally cutaneous (for the skin), but it does not specifically list or restrict every possible area of the body.

---

Q: Can using Detreomycyna 2% lead to a fungal or yeast infection?

Regulatory documents indicate that the use of this antibiotic may lead to an overgrowth of non-susceptible organisms, including fungi (superinfection). If non-susceptible organisms, such as fungi, begin to overgrow, this condition would typically be addressed as directed by a healthcare professional.

---

Q: Does Detreomycyna 2% interact with common pain relievers like paracetamol or ibuprofen?

Official regulatory sources have not generally reported an association between topical Chloramphenicol and interactions with common pain relievers like paracetamol or ibuprofen.

---

Q: Is there an interaction between Detreomycyna 2% and alcohol consumption?

Authoritative sources generally state that it is acceptable to consume alcohol while using the topical formulation. This is due to the low amount of the drug typically absorbed into the body from skin application.

---

Q: What kind of infections or skin conditions is Detreomycyna 2% not effective against?

The active substance in Detreomycyna 2% is classified as an antibacterial agent. Official documents state that it is not effective against fungi, viruses, or protozoa. Its use is limited to infections caused by susceptible bacteria.

---

Q: What happens if Detreomycyna 2% is accidentally swallowed or gets into the eye/ear?

Official information suggests that accidental ingestion of topical formulations is considered to be unlikely to lead to acute systemic toxicity, based on the low drug concentration. If the ointment gets into the eye, the typical advice is to flush the eye immediately.

---

Q: Does the application of Detreomycyna 2% require gloves or special hygiene practices?

Patient information typically suggests that users wash their hands thoroughly before and after applying the ointment. This practice is recommended to help prevent the potential spread of infection to other areas or other people.

---

Q: Can Detreomycyna 2% be used to prevent infection or only to treat an existing one?

The official therapeutic indication for the product is the treatment of localized bacterial infections. The regulatory documentation does not typically state its use is intended for preventing infection.

---

Q: Are there any food or dietary restrictions associated with using Detreomycyna 2%?

Authoritative sources generally state that there are no specific food or dietary restrictions associated with the use of the topical formulation of this medicine.

---

Q: Can Detreomycyna 2% be used on the scalp or near the hairline?

The product is officially indicated for topical application to the skin. Specific restrictions are not typically given for the scalp or hairline in the general product label.

---

Q: Does Detreomycyna 2% interfere with the healing process of a wound?

Official adverse event profiles for the cutaneous (skin) use of the ointment do not list interference with wound healing as a commonly reported adverse event.

---

Q: Is it common to have skin peeling or dryness while using Detreomycyna 2%?

The most frequently listed local side effects include localized reactions such as burning, stinging, itching, and redness. Dryness and peeling are generally less frequently cited as common or uncommon adverse reactions in official product labels for the skin ointment.

---

Q: Is there a known risk of developing a rash called contact dermatitis from Detreomycyna 2%?

Official adverse reaction lists include the potential for allergic skin reactions such as a rash or dermatitis. This may occur as a delayed hypersensitivity response to the active substance or other ingredients.

---

Q: Is it necessary to cover the area after applying the Detreomycyna 2% ointment?

The official method of administration involves applying a thin layer of the ointment to the affected area. Official instructions do not typically instruct the patient to cover the area following application.

---

Q: Is it possible to use Detreomycyna 2% on an open wound?

The product is indicated for the treatment of localized bacterial infections, often associated with breaks in the skin, such as in purulent skin diseases. Use is restricted to the established therapeutic indications of the drug.

---

Q: Does Detreomycyna 2% affect the effectiveness of vaccines, such as flu shots?

Regulatory interaction lists specifically mention that Chloramphenicol can potentially reduce the immune response when co-administered with certain vaccines (e.g., Cholera, BCG). Flu shots are not specifically listed in the current product information.

---

Q: How does the topical version of this drug compare to taking it by mouth in terms of side effect risk?

Official documents for the topical drug note the rare risk of systemic absorption and the associated rare, severe blood disorders (like aplastic anaemia), which is a safety concern highlighted for this type of medication.

---

Q: Is it safe to use Detreomycyna 2% while breastfeeding?

Official regulatory text states that Chloramphenicol may appear in breast milk, and consequently, use of the topical product is not recommended during the breastfeeding period.

---

Q: What are the ingredients in the Detreomycyna 2% ointment besides the active medicine?

Official documents list the active substance, Chloramphenicol, and the specific excipients (inactive ingredients) used in the formulation. These excipients are necessary to create the ointment base and stabilize the product.

---

Q: How quickly does Detreomycyna 2% typically start to work?

The drug is a bacteriostatic agent, meaning it immediately starts to prevent bacterial replication upon binding. However, official sources do not provide a specific patient-perceived timeline for when visible improvement of the infection will be noticed.

How to Store and Dispose of Detreomycyna 2%

Official regulatory documentation sets specific requirements for the storage and disposal of Detreomycyna 2% (Chloramphenicol 2% ointment) to maintain product stability and ensure environmental protection.

Storage Requirements

Condition	Requirement
Temperature	Store at a temperature below 25 C
Child Safety	Must be kept out of the sight and reach of children
Stability	Do not use past the official three-year expiry date

Disposal Instructions

Expired or unused Detreomycyna 2% must not be disposed of in household waste or flushed down the sewer system. To comply with environmental protection rules, the product must be returned to a pharmacist for proper pharmaceutical waste handling and disposal.